

TYRX[®]



Zero Infections in High-Risk Cardiac Device Replacements Reported with Use of TYRX Antibacterial Envelope

Prospective, Multicenter Study of 532 Case Matched Patients Showed 100% Reduction in Infections

Athens, Greece (June 26, 2013): Use of TYRX, Inc.'s AIGISRx[®] Antibacterial Envelope reduced major infection rates by 100% in patients undergoing Cardiovascular Implantable Electronic Device (CIED) replacement procedures compared to case-matched retrospective control patients. Investigators presented new interim results from the *Citadel / Centurion* Clinical Study today at the Late Breaking Clinical Trials session at the European Heart Rhythm Association (EHRA), EUROPACE 2013.

The *Citadel / Centurion* study is a prospective, multicenter clinical study in patients at high-risk for CIED infection who have their CIED implanted with the AIGISRx Antibacterial Envelope. The aim of the study is to evaluate the impact of the AIGISRx Antibacterial Envelope on major device infection and mechanical complication rates in the 12-months after implantation. Investigators at 55 US centers enrolled patients who were at high-risk for device infection because they were undergoing a CIED replacement procedure with either an implantable cardioverter-defibrillator (ICD), (*Citadel*), or a cardiac resynchronization therapy (CRT) device (*Centurion*).

Additional results from a planned interim analysis of the primary endpoints for the first 1,000 eligible patients after 90-days of follow up were presented by Dr. Charles A. Henrikson, the Chief of Electrophysiology at the Oregon Health Sciences University.

Key study highlights included:

- The *Centurion* arm of the study enrolled patients undergoing CIED replacement with a CRT and the AIGISRx Antibacterial Envelope, and compared them to case-matched control patients undergoing CIED replacement with a CRT and no AIGISRx.
- Case-matched controls were selected in reverse chronologic order, from the period before the AIGISRx was first implanted at each study site.
- The primary endpoints of the study were major CIED infection and CIED mechanical complication rates.

- An interim analysis of 3-month follow-up data from the first 1,000 eligible *Citadel / Centurion* patients demonstrated that there were no major infections in the 597 *Centurion* patients in this cohort (0.0%). A total of 532 *Centurion* patients had case-matched controls.
- When the 532 *Centurion* patients implanted with the AIGISRx were compared to the 532 control patients who did not receive AIGISRx (6 major CIED infections), there were significantly fewer major CIED infections in the group that received the AIGISRx (0.0% vs. 1.2%; P=0.03).
- There was no significant difference in the frequency of CIED mechanical complications in the group implanted with the AIGISRx, compared to the control patients who did not receive the AIGISRx (P=0.23).

“We continue to see that CIED infections are on the rise, are associated with significant morbidity, mortality, and cost, and present substantial challenges to patients, as well as the physicians who provide them care,” stated Charles A. Henrikson, MD, FHRP, Oregon Health Sciences University, Portland, Oregon. “The *Citadel / Centurion* study is a large prospective study enrolling patients at community, academic, and VA medical centers which will provide us with very useful clinical information on the use of the AIGISRx Antibacterial Envelope when used in a variety of patients at high risk for CIED infection.”

The *Citadel / Centurion* study is registered in the ClinicalTrials.gov registry of federally and privately supported clinical trials conducted in the US and around the world (www.ClinicalTrials.gov).

This study was funded by TYRX, Inc.

About European Heart Rhythm Society

The European Heart Rhythm Association (EHRA) is a registered branch of the ESC. Its aim is to improve the quality of life of the European population by reducing the impact of cardiac arrhythmias and reducing sudden cardiac death.

About TYRX, Inc.

TYRX, Inc. commercializes innovative, implantable combination drug+device products focused on infection control, including the AIGISRx[®] Antibacterial Envelope, designed to reduce surgical site infections associated with Cardiac Implantable Electronic Devices (CIEDs). AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including “superbugs” such as methicillin-resistant *S. aureus* (MRSA).*

For more information, please visit www.TYRX.com or www.HeartDeviceInfection.com.

*Data on file at TYRX and published Hansen *et al. Pacing Clin Electrophysiol.* 2009; 32(7):898-907.

###

CONTACTS:

Robert White
President and Chief Executive Officer
TYRX, Inc.
732.246.8676
info@TYRX.com

For Media:
Kureczka/Martin Associates
Joan Kureczka
415.690.0210
Joan@Kureczka-Martin.com

MKT-23-194 Rev 1